Publications by authors named "Ho Tan Dat"
Article Synopsis
- The study introduces a new assay called SPOT-MAS that combines multiple analysis techniques to detect different types of cancer using circulating tumor DNA (ctDNA).
- SPOT-MAS was tested on a large group of 738 patients with various cancers and 1550 healthy controls, successfully identifying cancers with a sensitivity of 72.4% and high specificity.
- The assay performs well for early-stage cancers and shows promise for being more cost-effective compared to other ctDNA tests due to its lower sequencing depth requirements.
Article Synopsis
- - Late detection of hepatocellular carcinoma (HCC) leads to a low survival rate, but liquid biopsy assays that detect circulating tumor DNA (ctDNA) offer a potential early non-invasive detection method; however, challenges exist due to normal cell mutations and tumor diversity.
- - Researchers developed a classification model using deep sequencing of 13 HCC-associated genes, analyzing ctDNA fragment length profiles to distinguish between HCC patients and healthy individuals.
- - The model demonstrated strong performance in identifying HCC, with an AUC of 0.88 and 89% sensitivity in the discovery cohort, and similar results in an independent validation cohort, indicating potential for further clinical studies.
Article Synopsis
- * Researchers identified unique methylation markers from cell-free DNA of HCC patients and used them to train machine learning models, which successfully differentiated HCC patients from high-risk individuals without the cancer in testing.
- * By integrating these methylation markers with existing serum biomarkers in a commercial test, they achieved improved detection accuracy for HCC, demonstrating potential for early diagnosis.
Background: Therapy with sofosbuvir-ledipasvir (SOF-LDV) has been very effective in chronic HCV genotype-1 in clinical trials and several real-world cohorts. However, the safety and efficacy data of SOF-LDV for HCV genotype-6 is quite limited.
Methods: This open-label, clinical experience evaluated the safety and efficacy of SOF-LDV with or without ribavirin (RBV) for 12-24 weeks in patients with HCV genotype-1 (n=356) and genotype-6 (n=175) in Vietnam between September 2015 and May 2017.
Background & Aims: Genotype 6 chronic hepatitis C (HCV) is encountered predominantly in Southeast Asia and data on optimal treatment strategy is limited. This study was aimed at assessing the rate and predictors of sustained virological response (SVR) in genotype 6 chronic HCV following 48 and 24 weeks of pegylated interferon and ribavirin therapy.
Methods: This investigator-initiated, open-label randomized trial was conducted in Vietnam between 2008 and 2010.